Physicians

Associate Director, Duke Heart Center
Chief Medical Officer, Duke Heart Network

Department / Division
Medicine / Medicine - Cardiology

Address
DUMC 3126
Durham, NC 27710

Appointment Telephone
919-681-5816

Office Telephone
919-681-4804

Fax Telephone
919-681-7644

Training

• MD, Duke University School of Medicine, 1975

Residency

• Medicine, Massachusetts General Hospital, 1975-1977
• Cardiology, Massachusetts General Hospital, 1977-1980

Clinical Interests
Interventional cardiac catheterization

Research Interests
My current research is focused on clinical trials and new device development for the treatment of coronary and peripheral vascular disease. I have also been a co-principle investigator for the Gusto IIb substudy comparing direct angioplasty vs thrombolytics for treatment of acute myocardial infarction. Our group has pioneered the use of coronary angioplasty techniques for the treatment of peripheral vascular disease.  Our program is the first U.S. site for Carotid Wallstent Clinical Trial, which is a randomized trial of the Wallstent versus carotid endarterectomy.  I am involved in the development of database tools to allow determination of clinical and economic outcomes in patients with coronary artery disease.  I am participating in the collaborative effort to combine interventional techniques and surgical techniques and perform state of the art minimally invasive coronary bypass grafting in a combined cardiac catheterization/surgical suite.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abbott Laboratories
• Daiichi Sankyo Co., Ltd
• Eli Lilly & Co.
• Frederick Medical Consultants
• Gilead Sciences, Inc.
• Halifax Regional Medical Center

Representative Publications
4. Jones RH, Kesler K, Phillips HR, Mark DB, Smith PK, Nelson CL, Newman MF, Reves JG, Anderson RW, Califf RM. Long term survival benefit of CABG and PTCA in patients with coronary artery disease. J Thoracic and Cardiovascular Surgery 111(5): 1013-25, 1996 (1996)

3. Phillips HR, Ohman EM, Labinaz M, Sketch MH, Jr., Stack RS. Use of the perfusion balloon as a primary dilation device. J Interventional Cardiol 7:17B-24B, 1995 (1995)

2. (Califf RM, Phillips HR, Hindman MC, Mark DB, Lee KL, Behar VS, Johnson RA, Pryor DB, Rosati RA, Wagner GS, Harrell FE: Prognostic value of a coronary artery jeopardy score. J Am Col Cardiol, 5:1055-63, 1985 (1985)

1. Phillips HR, Carter JE, Okada RD, Levine FH, Boucher CA, Osbakken M, Lappas D, Buckley MJ, Pohost GM: Serial changes in left ventricular ejection fraction in the early hours after aortocoronary bypass grafting. Chest 83(1): 28-34, 1983 (1983)

The GUSTO-IIb Angioplasty Substudy Investigators. An International Randomized Trial of 1138 Patients Comparing Primary Coronary Angioplasty versus Tissue Plasminogen activator for Acute Myocardial Infarction. N E Journal (submitted).